Biomarker Blood Test Detects Early Alzheimer’s Signals Years Before Evidence Appears on Brain Scans

Mass General Brigham researchers find that pTau217 blood tests detect Alzheimer’s progression earlier than PET scans, identifying at-risk adults years before symptoms.

By: AXL Media

Published: Apr 14, 2026, 11:39 AM EDT

Source: Information for this report was sourced from EurekAlert!

Shifting the Diagnostic Timeline

New research from the Mass General Brigham Neuroscience Institute is redefining the earliest detectable stages of Alzheimer’s disease. In a study published April 14, 2026, in Nature Communications, investigators found that measuring plasma phosphorylated tau 217 (pTau217) in the blood provides a predictive window that opens years before current gold-standard imaging techniques. While PET scans have traditionally been viewed as the earliest warning system—detecting amyloid accumulation 10 to 20 years before symptoms—this new data suggests that pTau217 levels fluctuate and signal danger well before clear abnormalities manifest on those scans.

Findings from the Harvard Aging Brain Study

The researchers reached these conclusions after following 317 cognitively healthy volunteers from the Harvard Aging Brain Study (HABS) for an average of eight years. Participants, aged 50 to 90, underwent regular blood tests, PET scans, and cognitive assessments. The longitudinal data revealed that higher baseline levels of pTau217 were directly correlated with a faster rate of future amyloid buildup and subsequent cognitive decline. Conversely, the study found that individuals with low pTau217 levels were remarkably unlikely to develop significant brain pathology or cognitive impairment for several years, offering a reliable indicator of long-term stability.

A Scalable Alternative to Invasive Procedures

The clinical significance of this study lies in its potential to replace more expensive and invasive diagnostic methods. Currently, identifying Alzheimer's pathology often requires lumbar punctures (spinal taps) or high-cost PET imaging. Lead author Dr. Hyun-Sik Yang emphasizes that pTau217 testing could serve as a "first-step" screen, allowing doctors to identify at-risk patients during routine health maintenance. By simplifying the screening process, healthcare systems could more efficiently monitor aging populations and identify candidates for early intervention before irreversible brain damage occurs.